Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
180 Life Sciences Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ATNF
Nasdaq
2834
https://180lifesciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 180 Life Sciences Corp
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
- Mar 14th, 2024 12:30 pm
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
- Feb 26th, 2024 12:00 pm
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
- Dec 4th, 2023 2:00 pm
180 Life Sciences Announces Review of Strategic Alternatives
- Nov 28th, 2023 2:00 pm
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
- Aug 14th, 2023 8:29 pm
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
- Aug 10th, 2023 12:46 pm
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
- Aug 7th, 2023 1:00 pm
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
- Aug 3rd, 2023 12:00 pm
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
- Jul 31st, 2023 12:00 pm
Scroll